Last reviewed · How we verify
Methoxyflurane (M)
Methoxyflurane is a volatile halogenated ether anesthetic that depresses the central nervous system to produce anesthesia and analgesia.
Methoxyflurane is a volatile halogenated ether anesthetic that depresses the central nervous system to produce anesthesia and analgesia. Used for Acute pain relief and anxiety (sub-anesthetic doses), General anesthesia (historical use, largely discontinued).
At a glance
| Generic name | Methoxyflurane (M) |
|---|---|
| Also known as | NaCl |
| Sponsor | Oslo University Hospital |
| Drug class | Volatile halogenated ether anesthetic |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Acute Pain Management |
| Phase | FDA-approved |
Mechanism of action
Methoxyflurane acts as a general anesthetic by enhancing inhibitory GABAergic neurotransmission and inhibiting excitatory glutamatergic signaling in the central nervous system. It was historically used for general anesthesia and analgesia but has been largely withdrawn from many markets due to nephrotoxicity concerns associated with its metabolites. In recent years, it has been reintroduced in some regions (including Europe) at sub-anesthetic doses for acute pain relief and anxiety.
Approved indications
- Acute pain relief and anxiety (sub-anesthetic doses)
- General anesthesia (historical use, largely discontinued)
Common side effects
- Nephrotoxicity (at higher doses)
- Hepatotoxicity
- Dizziness
- Nausea and vomiting
- Headache
Key clinical trials
- Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |